

Confidence in serology without biopsy



**ProCeDE study:
EliA Celikey has best-in-class
performance in celiac disease¹**

Find out more at thermofisher.com/EliA

ThermoFisher
SCIENTIFIC

The ProCeDE study reinforces the outstanding clinical relevance of EliA Celikey IgA^{1,2}


ProCeDE is a large, international prospective study which validates the ESPGHAN approach of giving guidance on the diagnosis of celiac disease without the need for biopsy, in patients with symptoms suggestive of celiac disease.

The study compares tTG IgA diagnostic kits from 8 different manufacturers, across 33 centres over several years, involving samples from >700 patients aged 18 or under. Therefore this is a study of outstanding quality.

Outcome:


- The validity of the ESPGHAN approach was proven for all the tTG IgA tests included
- In symptomatic patients HLA analyses did not increase the diagnostic accuracy

EliA Celikey IgA




Reaches PPV=99% at
2x ULN

Competitor A



Reaches PPV=99%
at 4-5x ULN

Competitor B



Reaches PPV=99%
at 5-6x ULN

Results determined using recommended manufacturer cut-offs.
Figure adapted from Werkstetter KJ, et al. 2017.¹

Use EliA Celikey to diagnose celiac disease without a biopsy

EliA Celikey IgA achieves a PPV=99% with results as low as double the ULN. This diagnostic accuracy has been shown as outstanding compared to other tests.¹

The EliA quality you expect

Fully automated autoimmunity testing for high operational efficiency

Accurate and reproducible test results

Ensure high security in making a correct diagnosis

ESPGHAN: European Society of Pediatric Gastroenterology, Hepatology and Nutrition Serological tests
PPV: positive predictive value
ULN: upper limit of normal

References: 1. Werkstetter KJ, et al. *Gastroenterology* 2017; doi: 10.1053/j.gastro.2017.06.002 [epub ahead of print]. 2. Husby S, et al. *Journal Pediatric Gastroenterology and Nutrition* 2012; 54(1): 136-160.